Citigroup Inc Vanda Pharmaceuticals Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 69,504 shares of VNDA stock, worth $333,619. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,504

Previous 15,070 361.21%

Holding current value

$333,619

Previous $85,000 282.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.61 - $6.34 $250,940 - $345,111	54,434 Added 361.21%	69,504 $325,000
Q2 2024 Aug 12, 2024	BUY	$3.91 - $6.5 $13,008 - $21,625	3,327 Added 28.33%	15,070 $85,000
Q1 2024 May 10, 2024	BUY	$3.47 - $4.61 $8,616 - $11,446	2,483 Added 26.81%	11,743 $48,000
Q4 2023 Feb 09, 2024	BUY	$3.38 - $4.58 $26,860 - $36,397	7,947 Added 605.26%	9,260 $39,000
Q3 2023 Nov 09, 2023	SELL	$4.28 - $6.57 $484,953 - $744,426	-113,307 Reduced 98.85%	1,313 $5,000
Q2 2023 Aug 10, 2023	SELL	$5.9 - $6.95 $632,657 - $745,248	-107,230 Reduced 48.33%	114,620 $755,000
Q1 2023 May 11, 2023	BUY	$6.18 - $7.99 $703,382 - $909,389	113,816 Added 105.35%	221,850 $1.51 Million
Q4 2022 Feb 09, 2023	SELL	$6.87 - $10.96 $356,449 - $568,659	-51,885 Reduced 32.44%	108,034 $798,000
Q3 2022 Nov 10, 2022	BUY	$9.44 - $11.76 $400,633 - $499,094	42,440 Added 36.13%	159,919 $1.58 Million
Q2 2022 Aug 10, 2022	BUY	$9.31 - $11.84 $326,734 - $415,524	35,095 Added 42.6%	117,479 $1.28 Million
Q1 2022 May 12, 2022	SELL	$10.84 - $16.55 $753,271 - $1.15 Million	-69,490 Reduced 45.76%	82,384 $932,000
Q4 2021 Feb 10, 2022	BUY	$15.69 - $21.14 $918,147 - $1.24 Million	58,518 Added 62.68%	151,874 $2.38 Million
Q3 2021 Nov 10, 2021	BUY	$15.35 - $21.27 $1.43 Million - $1.99 Million	93,356 New	93,356 $1.6 Million

Others Institutions Holding VNDA

# of Institutions

156

Shares Held

44.7M

Call Options Held

167K

Put Options Held

33.6K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account